REGENXBIO Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $170.4 | $83.3 | $90.2 | $112.7 | $470.3 |
| Operating income | -$161.2 | -$233.3 | -$268.1 | -$262.9 | $160.0 |
| Net income | -$193.9 | -$227.1 | -$263.5 | -$280.3 | $127.8 |
| Cash Flow Statement | |||||
| Free cash flow | -$126.4 | -$175.6 | -$228.4 | -$238.2 | $134.7 |
Shares outstanding 66.0M · Free float 87.0%
Annual filing data through FY ended December 31, 2025; float as of September 11, 2026.